RU2018133693A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018133693A3 RU2018133693A3 RU2018133693A RU2018133693A RU2018133693A3 RU 2018133693 A3 RU2018133693 A3 RU 2018133693A3 RU 2018133693 A RU2018133693 A RU 2018133693A RU 2018133693 A RU2018133693 A RU 2018133693A RU 2018133693 A3 RU2018133693 A3 RU 2018133693A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| US62/311,697 | 2016-03-22 | ||
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021115958A Division RU2021115958A (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018133693A3 true RU2018133693A3 (enExample) | 2020-04-22 |
| RU2018133693A RU2018133693A (ru) | 2020-04-22 |
| RU2749399C2 RU2749399C2 (ru) | 2021-06-09 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021115958A RU2021115958A (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
| RU2018133693A RU2749399C2 (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021115958A RU2021115958A (ru) | 2016-03-22 | 2017-03-22 | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (enExample) |
| EP (3) | EP4385981A1 (enExample) |
| JP (4) | JP7073270B2 (enExample) |
| KR (4) | KR20250057132A (enExample) |
| CN (3) | CN114716387B (enExample) |
| AU (1) | AU2017238181B2 (enExample) |
| BR (1) | BR112018069507A2 (enExample) |
| CA (1) | CA3018709A1 (enExample) |
| CL (1) | CL2018002683A1 (enExample) |
| CY (1) | CY1124487T1 (enExample) |
| DK (2) | DK3433238T3 (enExample) |
| ES (2) | ES2877572T3 (enExample) |
| FI (1) | FI3925952T3 (enExample) |
| HR (2) | HRP20211386T1 (enExample) |
| HU (2) | HUE065327T2 (enExample) |
| LT (2) | LT3925952T (enExample) |
| MX (1) | MX384823B (enExample) |
| PH (1) | PH12018502048A1 (enExample) |
| PL (2) | PL3925952T3 (enExample) |
| PT (2) | PT3433238T (enExample) |
| RS (2) | RS62274B1 (enExample) |
| RU (2) | RU2021115958A (enExample) |
| SA (1) | SA518400103B1 (enExample) |
| SI (2) | SI3433238T1 (enExample) |
| TR (1) | TR201813644T1 (enExample) |
| WO (1) | WO2017165473A1 (enExample) |
| ZA (1) | ZA201806389B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| DK3723815T3 (da) * | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| DK3498308T3 (da) * | 2017-12-13 | 2025-01-02 | Sciencons AS | Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid |
| PH12020551205A1 (en) * | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| WO2019157037A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| KR102156385B1 (ko) * | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| EP4556031A3 (en) * | 2018-04-27 | 2025-06-25 | University of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| CN121534209A (zh) * | 2018-09-28 | 2026-02-17 | 海德堡大学 | 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途 |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| KR20220044496A (ko) * | 2019-07-02 | 2022-04-08 | 어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘 | 전립선 특이적 막 항원(psma) 리간드 및 이의 용도 |
| CN114096526A (zh) * | 2019-07-02 | 2022-02-25 | 诺华股份有限公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| US20230097381A1 (en) * | 2020-04-24 | 2023-03-30 | Radiomedix, Inc. | Composition, kit and method for diagnosis and treatment of prostate cancer |
| IL297323A (en) * | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| WO2022108992A1 (en) * | 2020-11-17 | 2022-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| ES3053944T3 (en) * | 2020-11-19 | 2026-01-28 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| EP4355376A4 (en) * | 2021-06-17 | 2025-10-15 | Mayo Found Medical Education & Res | METHODS AND MATERIALS FOR COMBINING BIOLOGICALS WITH MULTIPLE CHELATORS |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| KR20250127126A (ko) * | 2022-12-21 | 2025-08-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| EP4746926A2 (en) | 2023-07-21 | 2026-05-27 | Novartis AG | Psma-targeting radioligand treatment regimen |
| WO2026124661A1 (zh) * | 2024-12-13 | 2026-06-18 | 长春金赛药业有限责任公司 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及其用途 |
| WO2026159621A1 (en) | 2025-01-23 | 2026-07-30 | Novartis Ag | Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002529A2 (en) * | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| AU2009322167B2 (en) * | 2008-12-05 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA |
| EP4420730A3 (en) | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| JP5843338B2 (ja) * | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| EP2785712B1 (en) * | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| HUE035739T2 (en) * | 2013-01-14 | 2018-05-28 | Molecular Insight Pharm Inc | Triazine-based radiopharmaceuticals and radiological imaging agents |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| ES2743482T3 (es) | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| US10112974B2 (en) * | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active IP Right Grant
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172559A patent/JP2026021351A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019008105A2 (enExample) | ||
| BR112019001429A2 (enExample) | ||
| BR112018068940A2 (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019011044B1 (pt) | Compostos de pirazol substituído, seu uso, e composição farmacêutica | |
| BR112019013070B1 (pt) | Aparelho de geração de energia | |
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019004968B1 (pt) | Misturador configurável | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (enExample) | ||
| CN303616157S (zh) | 保温瓶（rep） | |
| CN303623779S (zh) | 体外探头穿刺架 | |
| CN303634439S (zh) | 端子(l000332) | |
| CN303594122S (zh) | 童床（q酷宝贝） | |
| CN303627236S (zh) | 工艺品（丝路扬帆-小） | |
| CN303575245S (zh) | 3d装饰膜（起伏） | |
| CN303537476S (zh) | 飞碟吊椅 | |
| CN303536045S (zh) | 嫁衣（15） | |
| CN303536111S (zh) | 眼罩（条纹） | |
| CN303536110S (zh) | 眼罩（花纹） |